



NEWS RELEASE

Orion Nutraceuticals adds Clarice Thomas to Advisory Board

Vancouver, BC, February 21, 2019 – **Orion Nutraceuticals Inc.**, (CSE: **ORI**) (the “**Company**” or “**Orion**”) a cannabis life science company, is pleased to announce the addition of Clarice Thomas, to its advisory board.

As Co -Founder of I.O. Domani, a luxury retail boutique and other Co-Developing business ventures, located in Cabo San Lucas, Mexico she prides herself with being a focused and fearless negotiator. Clarice currently resides between Dallas, TX and Cabo San Lucas, Mexico.

Clarice Thomas joined ATV Broadcast as Vice President of New Media in 2012, after 20 years of marketing and sales project management. In 2014 Clarice and three business colleagues formed Belfor Media a sister company to ATV Broadcast syndicating internationally distribution and digital media globally, with offices in Dallas, London, New York and Indianapolis. Clarice has experience in both the public and private sectors including Director of Marketing for DBC America based in Helsinki, Finland. Clarice also served as Chief Administration Officer at Pinnacle Excavation specializing in underground utilities. Clarice Thomas Inc was founded in 2006 she served as the Relationship Consultant, acting as the liaison between the developers and retailers, interacted with resources in the private equity and hedge fund space for identifying viable investors.

Clarice’s expertise includes: Building functional collaborative teams and is recognized for her leadership abilities driving and responding to market trends, producing top sales practices, methodologies, relationship building skills, project management and branding identity. Clarice has set a presence in C.S.L., Mexico as being a minority woman & partner in a Mexican based construction company, interior design, manufacturing, logistics and vendor sourcing.

In 2015 Clarice joined EAST CAPE 65, LLC to oversee Business Development for the real estate resort hotel project in San Jose Del Cabo, Mexico. Handpicked as key member of management team to assist with launch of \$200MM+ resort hotel/real estate/spa/restaurant in Mexico from initial funding to pre-construction project. Clarice will wear multiple hats to assist overseeing: strategic planning/execution, feasibility studies reporting, local municipal relationships/entitlement, identifying multi-phased funding, sales, client/partner relationships, contract negotiations/operations, project management, to local vendor sourcing; along with working hand in hand with Dallas Based Developer Gate House Capital and Nunzio Marc DeSantis Architects also of Dallas, TX.

“We are excited to announce Clarice Thomas will be joining Orion Nutraceutical’s advisory board”, said Jonathan Fiteni, CEO of Orion. “Her business experience and connections will prove to be invaluable in developing new products, connecting Orion with sports professionals and furthering our stated goal of becoming a global presence in the world of sports medicine”.

STOCK OPTION GRANT

The Company also wishes to announce that it has granted incentive stock options of the Company to Clarice Thomas for the right to purchase up to an aggregate of 300,000 common shares of the Company, exercisable at the price of \$0.215 per share for two years. The effective date of the grant of



option is January 15, 2019. The options will vest in 2 tranches of 150,000 options each, with the first 150,000 options issued following the Company's announcement and the additional 150,000 options 6 months after. The stock options granted will be in accordance with the Company's Stock Option Plan and will have the required four months hold period legend, pursuant to the Policies of the CSE and regulatory authorities.

About Orion Nutraceuticals Inc.

Orion Nutraceuticals Inc. aims to set a new standard in cannabis life science by producing and developing innovative products with key strategic partners in the industry. In conjunction with its professional sports strategic alliances, the company is poised to advance research and development in the plant science sector, deliver science-based products and services, and market CBD therapies to the mainstream with proprietary brands and products. Medic-Oasis, Orion's subsidiary, has submitted its application for an ACMPR license and is currently under review with Health Canada. Build out is expected to begin in Q1 2019, with completion of the 30,000 square foot facility expected by Q3 2019. Orion Nutraceuticals is partners with Colombian based medical cannabis corporation FCM Global. FCM supplies pharmaceutical, nutritional, wellness, and cosmetic companies in legal markets worldwide with customized medical cannabis extracts, oils, and isolates at commercial scale. Orion shares trade in Canada on the CSE under the symbol ORI.

ON BEHALF OF THE BOARD

Jonathan Fiteni, CEO

Orion Nutraceuticals Inc. | www.orionnutra.ca

Investor Relations | Robin Linden, Director

1.604.313.2768 | investors@orionnutra.ca

Keep up to date with Orion on our social media channels:

Twitter: [@orionnutra](https://twitter.com/orionnutra) | Facebook: [@orionnutra](https://www.facebook.com/orionnutra) | Instagram: [@orionnutra](https://www.instagram.com/orionnutra) | LinkedIn: [@orionnutra](https://www.linkedin.com/company/orionnutra)

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.